Lakefront Biotherapeutics Announces New €50M Share Repurchase Program
Lakefront Biotherapeutics (LKFT) has launched a new share repurchase program with an authorization of up to €50 million. This follows the successful completion of a previous €50 million buyback on October 16, 2026, which involved the repurchase of approximately 1.99 million ordinary shares. The new mandate is scheduled to take effect on November 16, 2026, and will remain active through March 31, 2027. This move signals management's continued confidence in the company's capital allocation strategy and its commitment to returning value to shareholders.